Search in:

Advanced search

Leukemia & Lymphoma Volume 60, 2019 - Issue 8

Submit an article Journal homepage

403

Views

CrossRef citations to date

Altmetric

Original Article: Research

PET-derived tumor metrics predict DLBCL response and progression-free survival

Prioty IslamWinship Cancer Institute, Emory University, Atlanta, GA, USACorrespondence[email protected]
View further author information

Jordan GoldsteinWinship Cancer Institute, Emory University, Atlanta, GA, USAView further author information

Christopher R. FlowersWinship Cancer Institute, Emory University, Atlanta, GA, USAView further author information

Pages 1965-1971 | Received 14 Sep 2018, Accepted 12 Dec 2018, Published online: 04 Feb 2019

Cite this article
https://doi.org/10.1080/10428194.2018.1562181
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Cohen JB, Kurtz DM, Staton AD, et al. Next-generation surveillance strategies for patients with lymphoma. Future Oncol. 2015;11:1977–1991.
PubMed Web of Science ®Google Scholar
Cottereau AS, Lanic H, Mareschal S, et al. Molecular profile and FDG-PET metabolic volume at staging in DLBCL-response. Clin Cancer Res. 2016;22:3414–3415.
PubMed Web of Science ®Google Scholar
Cottereau AS, Lanic H, Mareschal S, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-Cell lymphoma. Clin Cancer Res. 2016;22:3801–3809.
PubMed Web of Science ®Google Scholar
Song MK, Yang DH, Lee GW, et al. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. Leuk Res. 2016;42:1–6.
PubMed Web of Science ®Google Scholar
Flowers CR, Shenoy PJ, Borate U, et al. Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma. 2013;54:268–276.
PubMed Web of Science ®Google Scholar
Pierce LA, 2nd, Elston BF, Clunie DA, et al. A digital reference object to analyze calculation accuracy of PET standardized uptake value. Radiology. 2015;277:538–545.
PubMed Web of Science ®Google Scholar
Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015;125:3679–3687.
PubMed Web of Science ®Google Scholar
Nguyen NC, Kaushik A, Wolverson MK, et al. Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study. Acta Oncol. 2011;50:670–677.
PubMed Web of Science ®Google Scholar
Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29:1822–1827.
PubMed Web of Science ®Google Scholar
Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60:393–408.
PubMed Web of Science ®Google Scholar
Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–842.
PubMed Web of Science ®Google Scholar
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
PubMed Web of Science ®Google Scholar
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
PubMed Web of Science ®Google Scholar
Koff JL, Flowers CR. Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: where do we go from here? Cancer. 2017;123:3222–3225.
PubMed Web of Science ®Google Scholar
Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124:2354–2361.
PubMed Web of Science ®Google Scholar
Reddy A, Zhang J, Davis NS, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481–494.e15.
PubMed Web of Science ®Google Scholar
Adams HJ, de Klerk JM, Fijnheer R, et al. CT-based versus FDG-PET/CT-based NCCN international prognostic index risk stratification in DLBCL. J Natl Compr Canc Netw. 2015;13:171–176.
PubMed Web of Science ®Google Scholar
Adams HJ, de Klerk JM, Fijnheer R, et al. Prognostic superiority of the national comprehensive cancer network international prognostic index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Eur J Haematol. 2015;94:532–539.
PubMed Web of Science ®Google Scholar
Adams HJ, Kwee TC. Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Br J Haematol. 2017;177:319–320.
PubMed Web of Science ®Google Scholar
Xie M, Wu K, Liu Y, et al. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2015;32:446.
PubMed Web of Science ®Google Scholar
Xie M, Zhai W, Cheng S, et al. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology. 2016;21:99–105.
PubMed Web of Science ®Google Scholar
Jiang M, Chen P, Ruan X, et al. Interim 18F-FDG PET/CT improves the prognostic value of S-IPI, R-IPI and NCCN-IPI in patients with diffuse large B-cell lymphoma. Oncol Lett. 2017;14:6715–6723.
PubMed Web of Science ®Google Scholar
Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma. Cancer. 2013;119:1195–1202.
PubMed Web of Science ®Google Scholar
Muringampurath-John D, Flowers CR, Toscano M, et al. Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leuk Lymphoma. 2012;53:725–727.
PubMed Web of Science ®Google Scholar
Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson center clinical experience. Br J Haematol. 2014;166:891–901.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

PET-derived tumor metrics predict DLBCL response and progression-free survival

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

PET-derived tumor metrics predict DLBCL response and progression-free survival

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date